Moderna Inc. stock reports cancer-vaccine results pre-market
Published on 10/23/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCancer vaccine results and agenda
- Moderna and Merck released results for the personalized cancer vaccine on October 22, 2026.
- Detailed results were scheduled for release on October 24, 2026.
- Moderna Inc. stock trades pre-market at EUR 179.50 at 7:55 a.m. CEST at Lang & Schwarz on October 23, 2026.
Moderna and Merck released results for their personalized mRNA cancer vaccine on October 22, 2026, according to the Charlotte Observer. Moderna Inc. stock trades pre-market at EUR 179.50 at 7:55 a.m. CEST at Lang & Schwarz on October 23, 2026.
Cancer vaccine results
The report said the Phase 3 INTerpath-001 trial evaluated intismeran autogene, a personalized mRNA melanoma vaccine, together with Merck’s Keytruda in patients with high-risk melanoma. The detailed results were scheduled for release on October 24, 2026, at a medical conference in Madrid. The source said Moderna and Merck subsequently released the trial results.
Ahead of the Xetra open
The stock is EUR 179.50 at Lang & Schwarz in pre-market trading on October 23, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Moderna stock.
Moderna and its business
Moderna develops mRNA medicines intended to prompt the immune system to create tools to treat or prevent disease, as described by the company on its website. The company-specific event on the agenda is the scheduled October 24, 2026, release of detailed cancer-vaccine results. Market context: Market report S&P 500.
